Regulatory & Legal

aTyr Pharma heads to a crucial FDA meeting for its lung drug efzofitimod, which missed its main goal but showed significant patient quality-of-life gains.

Weebit Nano's advanced memory is at the heart of a South Korean national program aiming to revolutionize AI with ultra-low-power compute-in-memory chips.

Outraged by Canada's enduring water crisis, Quebec high school students are taking their fight for Indigenous rights to the nation's capital.

With a strong cash position, ArriVent pushes its lead lung cancer drug toward a mid-2026 data readout while building a new pipeline in ADCs.

Scientists find herpes melts the inside of our cells to replicate faster, a discovery that could revolutionize treatments for a host of viral diseases.

New preclinical data shows Quanta Therapeutics' inhibitors remain potent against cancers that have developed resistance to advanced pan-RAS treatments.

Seal Shield's strategic acquisition of Vioguard and its FDA-cleared UV-C tech marks a major step forward in the battle against healthcare-associated infections.

Online tool retailer VEVOR makes a major move into physical stores, partnering with the Houston Rockets and opening its first global flagship in the city.

A new partnership aims to solve the flexible film waste crisis, spurred by tough new laws that are forcing the packaging industry to innovate or pay.

Newly published research brings scientific rigor to the controversial kratom plant, influencing policy from the FDA to statehouses across the nation.

BioRestorative Therapies is leveraging its clinical-grade regenerative medicine to disrupt the aesthetics industry. Can science beat marketing?

A new platform in Uzbekistan merges traditional banking with crypto under a state-led framework, offering a potential blueprint for global digital finance.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

Investors eye Moody's CEO Rob Fauber's upcoming speech for insights on AI strategy, M&A forecasts, and navigating an increasingly complex global economy.

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

Canada's top cannabis firm launches a fast-acting drink, leveraging brand power and nano-tech to shake up the evolving beverage market.

Select Medical's take-private deal at $16.50/share faces scrutiny as law firms question if shareholders are getting fair value from an insider-led group.

A novel oral drug for Alzheimer's avoids a key side effect of current therapies, as its 'detangler' platform shows promise for Parkinson's and other diseases.

A new report finds AI boosts elite team productivity 4x, but warns that automating mid-level tasks could create a critical cybersecurity skills gap.

The Rockefeller Foundation expands its Mission 300 Fellowship, embedding experts in 18 African nations to accelerate electrification and clean cooking access.